{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:18:12Z","timestamp":1791235092797,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["2022i01020004"],"award-info":[{"award-number":["2022i01020004"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2408085MH192"],"award-info":[{"award-number":["2408085MH192"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2308085MH310"],"award-info":[{"award-number":["2308085MH310"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejmech.2025.117436","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T04:16:57Z","timestamp":1740457017000},"page":"117436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discovery of potent, highly selective, and orally bioavailable factor XIa inhibitors for anticoagulant therapy"],"prefix":"10.1016","volume":"289","author":[{"given":"Yajing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zequn","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7080-1768","authenticated-orcid":false,"given":"Chenzhong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5864-304X","authenticated-orcid":false,"given":"Zhouling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117436_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40138-013-0014-6","article-title":"Anticoagulants: a review of the pharmacology, dosing, and complications","volume":"1","author":"Alquwaizani","year":"2013","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"10.1016\/j.ejmech.2025.117436_bib2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejmech.2025.117436_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/HPC.0b013e3181d29713","article-title":"The use and limitations of unfractionated heparin","volume":"9","author":"Krishnaswamy","year":"2010","journal-title":"Crit. Pathw. Cardiol."},{"key":"10.1016\/j.ejmech.2025.117436_bib4","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin : a statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2025.117436_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1753-4887.1999.tb01815.x","article-title":"Vitamin K: a practical guide to the dietary management of patients on warfarin","volume":"57","author":"Booth","year":"1999","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.ejmech.2025.117436_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11739-016-1411-0","article-title":"Why switch from warfarin to NOACs?","volume":"11","author":"Verdecchia","year":"2016","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ejmech.2025.117436_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/1570161113666150610093255","article-title":"Non-Vitamin K Oral Anticoagulants (NOACs) a review of clinical management and laboratory issues","volume":"14","author":"Blann","year":"2016","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117436_bib8","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","article-title":"Factor XIa inhibitors in anticoagulation therapy: recent advances and perspectives","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2025.117436_bib10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40265-024-02049-w","article-title":"Therapeutic potential of FXI inhibitors: hype or hope?","volume":"84","author":"Galli","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117436_bib11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.hoc.2016.05.007","article-title":"The intrinsic pathway of coagulation as a target for antithrombotic therapy","volume":"30","author":"Wheeler","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2025.117436_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1538-7836.2007.02446.x","article-title":"The intrinsic pathway of coagulation: a target for treating thromboembolic disease?","volume":"5","author":"Gailani","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2025.117436_bib13","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1021\/acs.jmedchem.4c00475","article-title":"Discovery of highly selective, potent, covalent, and orally bioavailable factor XIIa inhibitors for the ireatment of thrombo-inflammation","volume":"67","author":"Meng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"Duga","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ejmech.2025.117436_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2025.117436_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117436_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ejmech.2025.117436_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","article-title":"Factor XI inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement: a phase 2 clinical trial","volume":"44","author":"Pfeffer","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2025.117436_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117436_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/psp4.12663","article-title":"PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117436_bib21","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/17568919.2024.2409623","article-title":"Selective factor XI\/XIa inhibitors: a beacon of hope in anticoagulation therapy","volume":"16","author":"Xie","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib22","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib23","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1027627","article-title":"SHR2285, the first selectively oral FXIa inhibitor in China: safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117436_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000196","article-title":"EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: a brief report","volume":"2","author":"Pollack","year":"2020","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.ejmech.2025.117436_bib27","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study","volume":"87","author":"Beale","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117436_bib28","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1021\/acs.jmedchem.1c02153","article-title":"Targeting the S2 subsite enables the structure-based discovery of novel highly selective factor XIa inhibitors","volume":"65","author":"Yao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib29","doi-asserted-by":"crossref","first-page":"10419","DOI":"10.1021\/acs.jmedchem.2c00442","article-title":"Discovery of potent and orally bioavailable pyridine N-Oxide-based factor XIa inhibitors through exploiting nonclassical interactions","volume":"65","author":"Xu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib30","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1021\/acs.jmedchem.0c00279","article-title":"Structure-based design and preclinical characterization of selective and orally bioavailable factor XIa inhibitors: demonstrating the power of an integrated S1 protease family approach","volume":"63","author":"Lorthiois","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib31","first-page":"727","volume":"vol. 10","author":"Zhang","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117436_bib32","author":"Bayer"},{"key":"10.1016\/j.ejmech.2025.117436_bib33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40119-022-00266-6","article-title":"Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a factor XIa inhibitor","volume":"11","author":"Perera","year":"2022","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.ejmech.2025.117436_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112137","article-title":"Discovery and development of plasma kallikrein inhibitors for multiple diseases","volume":"190","author":"Xie","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib35","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/0006-2952(93)90004-G","article-title":"Cytotoxic effects of biphenyl and hydroxybiphenyls on isolated rat hepatocytes","volume":"45","author":"Nakagawa","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117436_bib36","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.bmc.2016.03.062","article-title":"Orally bioavailable pyridine and pyrimidine-based factor XIa inhibitors: discovery of the methyl N-phenyl carbamate P2 prime group","volume":"24","author":"Corte","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib37","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/prot.10259","article-title":"Kinase inhibitors and the case for CH.O hydrogen bonds in protein-ligand binding","volume":"49","author":"Pierce","year":"2002","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2025.117436_bib38","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2025.117436_bib39","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1021\/acs.jmedchem.2c01693","article-title":"The identification of potent, selective, and brain penetrant PI5P4Kgamma inhibitors as in vivo-ready tool molecules","volume":"66","author":"Rooney","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117436_bib40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/jth.15593","article-title":"XJ-8, a natural compound isolated from Sanguis draxonis, inhibits platelet function and thrombosis by targeting MAP3K3","volume":"20","author":"Zhu","year":"2022","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2025.117436_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfluchem.2020.109516","article-title":"Methyl-2,2-difluoro-2-(fluorosulfonyl) acetate (MDFA)\/copper (I) iodide mediated and tetrabutylammonium iodide promoted trifluoromethylation of 1-aryl-4-iodo-1,2,3-triazoles","volume":"236","author":"Panja","year":"2020","journal-title":"J. Fluor. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T13:24:05Z","timestamp":1749043445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425002016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"alternative-id":["S0223523425002016"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117436","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent, highly selective, and orally bioavailable factor XIa inhibitors for anticoagulant therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117436"}}